Scientific Excellence and Clinical Innovationat the 2026 Hadassah Hematology Conference – RFHMO
Research Fund of the Hadassah Medical Organization (RFHMO) shared a post on LinkedIn:
“On February 12-13, 2026, the Hematology Division at Hadassah convened its annual Research Conference at the Dan Panorama Hotel in Tel Aviv – two intensive days dedicated to scientific excellence, clinical innovation, and interdisciplinary collaboration.
The conference reflected the division’s deep and sustained engagement in research across the full spectrum of hematology. The majority of presentations were conducted by physicians of the department and under their direct supervision, highlighting a strong culture of inquiry spanning basic, translational, and clinical research.
Scientific sessions addressed cutting-edge studies in multiple myeloma and amyloidosis, acute leukemias, lymphoma and CLL, MDS and MPN, coagulation and plasmapheresis, bone marrow transplantation and CAR-T therapies, as well as supportive and palliative medicine.
Annual updates summarized the latest international advances, reinforcing Hadassah’s position at the forefront of global hematologic research.
Beyond scientific depth, the conference emphasized the essential link between research and high-quality patient care. Active research does not exist in isolation, it directly translates into improved diagnostics, innovative therapies, and better clinical outcomes.
A dedicated session on medical education further underscored the division’s commitment to training the next generation of physician-scientists, strengthening Hadassah’s academic identity as a leader in clinical excellence, research innovation, and medical education.
At RFHMO, we are proud to support the research ecosystem that enables these achievements – fostering collaboration, empowering clinicians, and ensuring that scientific discovery continues to shape the future of hematologic care.
Follow RFHMO to stay connected with the research driving tomorrow’s medicine at Hadassah.”
Stay updated with Hemostasis Today.
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:15Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics
-
Jul 3, 2026, 18:24Alexandros Rampotas: Targeting Mutant CALR With Precision CAR-T Therapy
-
Jul 3, 2026, 18:08Ram Khandelwal: Why AI Is Transforming Patient Education and the Future of Healthcare
-
Jul 3, 2026, 17:55Miguel Bronchud: Why Congenital Neutropenia Is Often Missed
-
Jul 3, 2026, 17:35Patrick Rensen: Celebrating 25 Years in Endocrinology at Leiden University Medical Center